CVS forecast an adjusted profit of $1.14- $1.17 per share for the first quarter, below the average analyst estimate of $1.18, according to Thomson Reuters I/B/E/S. The net income attributable to the company rose 13.4 percent to $1.50 billion, or $1.34 per share, in the fourth quarter ended Dec. 31, helped by strong demand in its pharmacy business.» Read More
Orexigen's obesity pill is called Contrave, and it's been approved in the U.S. CNBC's Meg Tirrell reports.
The UN food price index has dipped to a four-year low as good weather has resulted in an oversupply of cereals and dairy imports have slowed.
Walgreen is naming Jana founder Rosenstein to its board and the activist investor will get a say in choosing at least one additional director.
CNBC's Meg Tirrell reports the Drug Enforcement Administration is changing the rules around pain drugs like Vicodin. The drugs will be deemed "schedule 2 substances," versus the less restrictive "schedule 3."
CNBC's Meg Tirrell provides insight to the definition of obesity by the CDC, and which drug companies are working on treatments in the space.
A massive fire in Northern California has so far burned close to 12,000 acres and injured 12 people. CNBC's Jane Wells reports on the costs to the state, as well as to marijuana growers.
Dr. Beth Bell, CDC Infectious Diseases Center, discusses the Ebola crisis in West Africa, and the risks to U.S. citizens. Bell explains current experimental treatments.
The CDC Director is testifying before Congress on Ebola, and pharma companies are scrambling to create drugs to help. CNBC's Meg Tirrell, and Michael Yee, RBC Capital Markets, discuss some of these companies.
Viagra's patent in China has expired and some analysts expect cheaper prices will bring a surge of demand for the storied erectile dysfunction drug.
Insurance companies are hurting from the high cost of hepatitis C drug Sovaldi. Arthur Caplan, NYU Langone Medical Center, and CNBC's Bertha Coombs, share their opinions.
CNBC's Bertha Coombs reports which insurance stocks are hurting from the high cost of hepatitis C Sovaldi.
CNBC's Bertha Coombs reports which insurance stocks are feeling the pressure from high drug costs. FMHR trader Stephen Weiss advises investors to stick with Gilead.
CNBC's Scott Cohn reports FedEx has been indicted on 15 criminal counts for helping Internet pharmacies deliver drugs to buyers in the U.S. without prescriptions.
CNBC's Meg Tirrell reports which biotech companies are working on what analysts say could be the next big biotech catalyst known as NASH, or nonalcoholic steatohepatitis.
David Dinenberg, Kind Banking founder and CEO, provides insight to his business model of providing financing to the new legal pot industry.
The FDA approved MannKind's inhaled insulin drug Afrezza. CNBC's Meg Tirrell has the details of the approval.
Paid members of the Arcview Group have committed to investing at least $50,000 into the budding cannabis industry. Members are in Denver hearing pitches from pot start-ups, reports CNBC's Josh Lipton.
Incyte CEO Herve Hoppenot, provides insight to his company's progress on cancer research at this year's ASCO conference.
Ariad Pharmaceuticals CEO Dr. Harvey Berger, says investors are responding to his company's better overall picture, and the progress on its leukemia drug Iclusig.
In the U.S., half of all men and a third of all women will develop cancer in their lifetimes. CNBC's Meg Tirrell reports which stocks analysts are eyeing into the conference.